PMID- 34050690
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 112
IP  - 9
DP  - 2021 Sep
TI  - CAR-NK cell in cancer immunotherapy; A promising frontier.
PG  - 3427-3436
LID - 10.1111/cas.14993 [doi]
AB  - Chimeric antigen receptors (CARs) have a unique facet of synthetic biology and 
      offer a paradigm shift in personalized medicine as they can use and redirect the 
      patient's immune cells to attack cancer cells. CAR-natural killer (NK) cells 
      combine the targeted specificity of antigens with the subsequent intracellular 
      signaling ability of the receptors to increase their anti-cancer functions. 
      Importantly, CAR-NK cells can be utilized as universal cell-based therapy without 
      requiring human leukocyte antigen (HLA) matching or earlier contact with 
      tumor-associated antigens (TAAs). Indeed, CAR-NK cells can be adapted to 
      recognize various antigens, hold higher proliferation capacity, and in vivo 
      persistence, show improved infiltration into the tumors, and the ability to 
      overcome the resistant tumor microenvironment leading to sustained cytotoxicity 
      against tumors. Accumulating evidence from recent in vivo studies rendering 
      CAR-NK cell anti-cancer competencies renewed the attention in the context of 
      cancer immunotherapy, as these redirected effector cells can be used in the 
      development of the "off-the-shelf" anti-cancer immunotherapeutic products. In the 
      current review, we focus on the therapeutic efficacy of CAR-NK cell therapies for 
      treating various human malignancies, including hematological malignancies and 
      solid tumors, and will discuss the recent findings in this regard, with a special 
      focus on animal studies.
CI  - (c) 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Marofi, Faroogh
AU  - Marofi F
AUID- ORCID: 0000-0002-8110-7808
AD  - Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Abdul-Rasheed, Omar F
AU  - Abdul-Rasheed OF
AD  - Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain 
      University, Baghdad, Iraq.
FAU - Rahman, Heshu Sulaiman
AU  - Rahman HS
AD  - Department of Physiology, College of Medicine, University of Suleimanyah, 
      Suleimanyah, Iraq.
FAU - Budi, Hendrik Setia
AU  - Budi HS
AD  - Department of Oral Biology, Faculty of Dental Medicine, Universitas Airlangga, 
      Surabaya, Indonesia.
FAU - Jalil, Abduladheem Turki
AU  - Jalil AT
AUID- ORCID: 0000-0001-8403-7465
AD  - Faculty of Biology and Ecology, Yanka Kupala State University of Grodno, Grodno, 
      Belarus.
FAU - Yumashev, Alexei Valerievich
AU  - Yumashev AV
AD  - Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Hassanzadeh, Ali
AU  - Hassanzadeh A
AD  - Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Yazdanifar, Mahboubeh
AU  - Yazdanifar M
AD  - Department of Pediatrics, Stem Cell Transplantation and Regenerative Medicine, 
      Stanford University School of Medicine, Palo Alto, CA, USA.
FAU - Motavalli, Roza
AU  - Motavalli R
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Chartrand, Max Stanley
AU  - Chartrand MS
AD  - DigiCare Behavioral Research, Casa Grande, AZ, USA.
FAU - Ahmadi, Majid
AU  - Ahmadi M
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Cid-Arreguid, Angel
AU  - Cid-Arreguid A
AD  - Targeted Tumor Vaccines Unit, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
FAU - Jarahian, Mostafa
AU  - Jarahian M
AD  - German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), 
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210707
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Genetic Engineering/methods
MH  - Genetic Vectors
MH  - Hematologic Neoplasms/*therapy
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Killer Cells, Natural/*immunology
MH  - Mice
MH  - Receptors, Chimeric Antigen/genetics/*immunology
MH  - Treatment Outcome
MH  - Tumor Microenvironment
MH  - Xenograft Model Antitumor Assays
PMC - PMC8409419
OTO - NOTNLM
OT  - CAR-NK
OT  - cancer
OT  - chimeric antigen receptors
OT  - immunotherapy
OT  - natural killer cells
COIS- There is no conflict of interests.
EDAT- 2021/05/30 06:00
MHDA- 2021/09/15 06:00
PMCR- 2021/09/01
CRDT- 2021/05/29 08:35
PHST- 2021/05/12 00:00 [revised]
PHST- 2021/04/10 00:00 [received]
PHST- 2021/05/23 00:00 [accepted]
PHST- 2021/05/30 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2021/05/29 08:35 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - CAS14993 [pii]
AID - 10.1111/cas.14993 [doi]
PST - ppublish
SO  - Cancer Sci. 2021 Sep;112(9):3427-3436. doi: 10.1111/cas.14993. Epub 2021 Jul 7.